

January 29, 2021

Zavation Medical Products, LLC Katie Motley Design Engineer 220 Lakeland Parkway Flowood, Mississippi 39232

Re: K202398

Trade/Device Name: Ti3Z Cervical Interbody System

Regulation Number: 21 CFR 888.3080

Regulation Name: Intervertebral Body Fusion Device

Regulatory Class: Class II

Product Code: ODP

Dated: December 23, 2020 Received: December 28, 2020

Dear Katie Motley:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Brent Showalter, Ph.D.
Assistant Director
DHT6B: Division of Spinal Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2020 See PRA Statement below.

K202398	K202398 Page 1 of 1
Device Name Ti 3Z Cervical Interbody System	

Indications for Use (Describe)

When used as a cervical intervertebral body fusion device, the Zavation Ti 3Z Cervical Interbody System implants are intended to be used with autograft or allogenic bone graft comprised of cancellous and/or corticancellous bone graft in skeletally mature patients. The Ti3Z cervical implants are intended for use at one level in the cervical spine, from C2 to T1, for the treatment of cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies). The cervical device is intended to be used in patients who have had six weeks of non-operative treatment.

For all the above indications the Zavation Ti 3Z Cervical Interbody implants are intended to be used with supplemental internal fixation appropriate for the implanted level, including Zavation Cervical Plate System.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510K Summary

Date: September 9, 2020

Submitter: Zavation Medical Products, LLC

220 Lakeland Pkwy Flowood, MS 39232 Phone: 601-919-1119 Fax: 800-447-1302

Contact person: Katie Motley

Type of 510(k) submission: Traditional

Trade name: Ti 3Z Cervical Interbody System

Common name: Intervertebral Body Fusion Device

Classification regulation: 21 CFR 888.3080 Intervertebral body fusion device

Device classification: Class II

Classification Panel: Orthopedic

Product code: ODP

Basis for submission Addition of Ti3Z-PEEK cervical implant

Device Description:

The Zavation Ti3Z Cervical Interbody System implants are offered in two configurations: Ti3Z cervical implants are additively manufactured entirely from medical grade Titanium Ti64ELI powder by way of laser sintering (ASTM F3001); Ti3Z-PEEK cervical implants have an exterior that is manufactured from medical grade PEEK (polyetheretherketone) with tantalum beads or pins embedded in the implants to allow for radiographic visualization. Ti3Z-PEEK implants also contain an interior titanium insert manufactured by way of laser sintering (ASTM F3001) and a wrought titanium pin (ASTM F136). The ends of the Ti3Z-PEEK implants have machined teeth which are designed to engage with the vertebral body end plates.

The Zavation Ti 3Z Cervical and Ti3Z-PEEK Cervical Interbody implants are available in a range of heights, widths and lengths as well as parallel and lordotic angled implants, to accommodate variations in patients' anatomy. The internal body of both constructs have a porous structure while the external edges of the implants have a solid, roughened surface designed to engage with the vertebral body end plates. Both porous and solid aspects of the Ti3Z cervical implant are printed simultaneously. This modification seeks clearance for the addition of Ti3Z-PEEK cervical spacers. All implants will be provided sterile.

Intended Use:

When used as a cervical intervertebral body fusion device, the Zavation Ti 3Z Cervical Interbody System implants are intended to be used with autograft or allogenic bone graft comprised of cancellous and/or corticancellous bone graft in skeletally mature patients. The Ti3Z cervical IBF implants are intended for use at one level in the cervical spine, from C2 to T1, for the treatment of cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies). The cervical device is intended to be used in patients who have had six weeks of non-operative treatment.

For all the above indications the Zavation Ti 3Z Cervical Interbody implants are intended to be used with supplemental internal fixation appropriate for the implanted level, including Zavation Cervical Plate System.

Materials:

The devices are manufactured from medical grade Titanium Ti6ALV 4ELI alloy (ASTM F3001-14) **OR** medical grade PEEK (ASTM F560) with Tantalum markers (ASTM F2026) and a medical grade Titanium Ti6ALV 4ELI alloy (ASTM F3001-14) insert and pin (ASTM F136).

Predicate Device:

Primary -Zavation IBF System, Zavation LLC (K181246)
Additional – ChoiceSpine Stealth Cervical Spacer System (K183397)
Additional - X-Spine Systems, Inc. Calix-C[™] Cervical Interbody Spacer (K171075)
Additional Predicate – Zavation Ti3Z Cervical Interbody System (K191354)
Reference Predicate – Zavation Ti 3Z Lumbar Interbody System (K180076)

Technological Characteristics:

The subject device is identical in surgical technique, and instrumentation to the primary predicate device cleared in (K181246) and additional predicate (K191354). The difference to the Zavation Ti3Z Cervical Interbody System is the addition of a Titanium (ASTM F3001) and PEEK combination implant with the titanium serving as an interior insert. Zavation Ti3Z-PEEK Cervical possesses the same technological characteristics as the primary predicate and reference predicate. These include similar heights, widths, lengths, and intended use.

Performance Data:

Mechanical test results demonstrated that the Zavation Ti 3Z- PEEK cervical spacer is substantially equivalent to the predicate devices. Testing was performed in accordance with:

- ASTM F2077
 - o Static Axial Compression
 - Dynamic Axial Compression
 - o Static Torsion
 - o Dynamic Torsion
 - o Static Shear
 - o Dynamic Shear
- ASTM F2267
 - o Subsidence
- Expulsion

Process Validation test results demonstrate that the Zavation Ti 3Z Lumbar Interbody System (K180076), Ti3Z Cervical Interbody System (K191354) and Zavation IBF System (K181246) are free from any possible contaminants and the cleaning process is adequate for implants to be provided sterile. The Zavation Ti 3Z-PEEK Cervical spacers' manufacturing, post processing, cleaning, sterilization, and packaging are identical to that of Zavation IBF System (K181246), Zavation Ti3Z Cervical System (K191354), and Zavation Ti3Z Lumbar System (K180076) and fall under current validated procedures. Testing was performed in accordance with:

- ASTM F 2847-10, Standard Practice for Reporting Assessment of Residues on Single Use Implants
 - o Gravimetric Analysis, ASTM F 2459-12
 - o Cytotoxicity, ISO 10993-5: 2009
 - o Total Organic Carbon
 - o Limulus Amebocyte Lysate (LAL) (Endotoxin)

Basis for Substantial Equivalence:

The Zavation Ti 3Z-PEEK cervical spacer devices are similar to the predicate systems with respect to technical characteristics, performance, and intended use. The information provided within this premarket notification supports substantial equivalence of the subject spacers to the predicate devices and is therefore safe and effective for its intended use.